Gefitinib, erlotinib, and icotinib are some of the first-generation drugs for treating NSCLC patients with EGFR-activating mutations (Exon 19 deletion and exon 21 L858R) (Tomasello et al. 2018). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.